project id: TCGA-UCEC; case submitter id: TCGA-AX-A3FT; source center: 23; state: released; a260 a280 ratio: 1.84; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.4; rna integrity number: 9.3; age at index: 64; days to birth: -23543; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1946; age at diagnosis: 23543; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 6.0; figo stage: Stage IB; icd 10 code: C54.1; last known disease status: not reported; morphology: 8380/3; primary diagnosis: Endometrioid adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: No; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 524; initial weight: 110.0; oct embedded: false; preservation method: Unknown; sample id: 6176a2e7-9c0b-4a9c-b8d6-cf669419959d; sample submitter id: TCGA-AX-A3FT-01A; portion id: 29302b27-6ee9-4a64-b0cf-165b15bbafe4; portion submitter id: TCGA-AX-A3FT-01A-11; slide id: a7e05063-a1f2-449a-bb2e-11aaa9d0985d; slide submitter id: TCGA-AX-A3FT-01A-01-TS1; percent lymphocyte infiltration: 10.0; percent monocyte infiltration: 0.0; percent necrosis: 2.0; percent neutrophil infiltration: 0.0; percent normal cells: 8.0; percent stromal cells: 20.0; percent tumor cells: 70.0; percent tumor nuclei: 80.0; section location: TOP;